{"denoms":[{"counts":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"16"},{"groupId":"BG002","value":"17"},{"groupId":"BG003","value":"36"}],"units":"Participants"}],"groups":[{"description":"Brentuximab vedotin 1.4 mg/kg, 30-minute IV infusion, Day 1 of every 21-day cycle, until there was evidence of disease progression or unacceptable toxicity.","id":"BG000","title":"Brentuximab Vedotin 1.4 mg/kg: Phase 1"},{"description":"Participants with r/r HL received brentuximab vedotin 1.8 mg/kg, 30-minute IV infusion, Day 1 of every 21-day cycle until there was evidence of disease progression or unacceptable toxicity (Up to 16 cycles). Treatment with brentuximab vedotin beyond 16 cycles was permitted at the joint discretion of the sponsor and the investigator for those participants experiencing continued clinical benefit.","id":"BG001","title":"Brentuximab Vedotin 1.8 mg/kg: Phase 1 and 2 r/r HL Only"},{"description":"Participants with r/r systemic anaplastic large-cell lymphoma (sALCL) received brentuximab vedotin 1.8 mg/kg, 30-minute IV infusion, Day 1 of every 21-day cycle until there was evidence of disease progression or unacceptable toxicity (Up to 16 cycles). Treatment with brentuximab vedotin beyond 16 cycles was permitted at the joint discretion of the sponsor and the investigator for those participants experiencing continued clinical benefit.","id":"BG002","title":"Brentuximab Vedotin 1.8 mg/kg: Phase 1 and 2 r/r sALCL Only"},{"description":"Total of all reporting groups","id":"BG003","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"1.15","value":"14.7"},{"groupId":"BG001","spread":"2.68","value":"14.5"},{"groupId":"BG002","spread":"3.18","value":"11.5"},{"groupId":"BG003","spread":"3.19","value":"13.1"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"7"},{"groupId":"BG002","value":"3"},{"groupId":"BG003","value":"11"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"9"},{"groupId":"BG002","value":"14"},{"groupId":"BG003","value":"25"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"4"},{"groupId":"BG003","value":"4"}],"title":"Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"14"},{"groupId":"BG002","value":"12"},{"groupId":"BG003","value":"29"}],"title":"Not Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"3"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Ethnicity (NIH/OMB)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"13"},{"groupId":"BG002","value":"16"},{"groupId":"BG003","value":"31"}],"title":"White"},{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"2"}],"title":"Asian"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"2"}],"title":"Other"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"1"}],"title":"Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Race/Ethnicity, Customized","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"4"}]}],"title":"United States"},{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"2"}]}],"title":"France"},{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"4"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"5"}]}],"title":"Germany"},{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"2"},{"groupId":"BG003","value":"3"}]}],"title":"Netherlands"},{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"2"},{"groupId":"BG003","value":"3"}]}],"title":"United Kingdom"},{"categories":[{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"7"},{"groupId":"BG002","value":"6"},{"groupId":"BG003","value":"14"}]}],"title":"Italy"},{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"4"},{"groupId":"BG003","value":"4"}]}],"title":"Spain"},{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"1"}]}],"title":"Mexico"}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Region of Enrollment","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"10.865","value":"167.17"},{"groupId":"BG001","spread":"14.350","value":"165.31"},{"groupId":"BG002","spread":"17.783","value":"149.54"},{"groupId":"BG003","spread":"17.493","value":"158.02"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Height","unitOfMeasure":"cm"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"9.924","value":"53.10"},{"groupId":"BG001","spread":"17.539","value":"57.85"},{"groupId":"BG002","spread":"15.162","value":"42.16"},{"groupId":"BG003","spread":"17.361","value":"50.04"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Weight","unitOfMeasure":"kg"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"0.0967","value":"1.562"},{"groupId":"BG001","spread":"0.2938","value":"1.617"},{"groupId":"BG002","spread":"0.3103","value":"1.313"},{"groupId":"BG003","spread":"0.3228","value":"1.469"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Body Surface Area","unitOfMeasure":"m^2"}],"populationDescription":"Safety population is defined as participants who received at least 1 dose of study drug."}